DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Influence of Age and Sepsis on Rocuronium Pharmacokinetics

Information source: Universidade Estadual Paulista Jlio de Mesquita Filho
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sepsis; Systemic Inflammatory Response Syndrome; Septic Shock

Intervention: Serial blood sampling (Procedure); Train of four monitoring (Procedure); Blood testing for liver and renal function (Procedure); General anesthesia (Drug); Small to medium sized surgery under general anesthesia (Procedure)

Phase: Phase 4

Status: Recruiting

Sponsored by: Universidade Estadual Paulista Jlio de Mesquita Filho

Official(s) and/or principal investigator(s):
Natalia V. de Moraes, Prof., Principal Investigator, Affiliation: Universidade Estadual Paulista Júlio de Mesquita Filho

Overall contact:
Natalia V. de Moraes, Prof., Phone: +55 16 3301 4689, Email: nmoraes@fcfar.unesp.br

Summary

This study aims to evaluate the influence of age and sepsis on in vivo activity of OATP1A2 using rocuronium (ROC) as a probe and evaluating the pharmacokinetics and pharmacodynamics in ASA I-III surgical patients. Thus, adult patients without sepsis (control group, n= 12), adult patients with sepsis (sepsis group, n= 12) and elderly patients without sepsis (elderly group, n= 12), all submitted to small to medium-sized surgeries who were induced with individual doses of rocuronium, fentanyl and propofol are being investigated.

Clinical Details

Official title: Influence of Sepsis and Age on OATP1A2 Activity Using Rocuronium Pharmacokinetics-pharmacodynamics in Surgical Patients as a Model.

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Determination of AUC/dose

Secondary outcome:

Determination of total clearance

Determination of volume of distribution

Determination of mean residence time

OATP1A2 genotyping using Real Time-PCR

Analysis of cytokine IL-1α in plasma

Analysis of cytokine IL-1β in plasma

Analysis of cytokine IL-6 in plasma

Analysis of cytokine TNF-α in plasma

Pharmacokinetic-Pharmacodynamic analysis: relationship between rocuronium plasma concentration and the neuromuscular blockade

Detailed description: Rocuronium (ROC), a neuromuscular blocking agent used in surgical procedures, is primarily eliminated by biliary excretion. Its distribution to the liver, mediated the organic anion transporting polypeptide 1A2 (OATP1A2), is a determining factor for the duration of neuromuscular blockade. Age and release of cytokines during inflammation and infection processes of sepsis can alter expression of SLCO1A2 gene, encoding OATP1A2. The objective of this study is to evaluate the influence of age and sepsis on in vivo activity of OATP1A2 using ROC as a probe and evaluating the pharmacokinetics and pharmacodynamics in ASA I-III surgical patients. Adult patients without sepsis (control group, n=12), adult patients with sepsis (sepsis group, n=12) and elderly patients without sepsis (elderly group, n=12), all submitted to small to medium-sized surgeries are being investigated. All patients are being induced with individual doses of rocuronium, fentanyl and propofol. Serial blood samples are being collected up to 360 minutes after administration of ROC. Neuromuscular blockade induced by ROC is monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same times of blood sampling. The plasma concentration of ROC will be analyzed by liquid chromatography coupled to mass spectrometry with electrospray ionization using positive ion mode.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult and elderly patients, both gender.

- Patients submitted to small to medium-sized surgeries.

- Patients who were induced with individual doses of rocuronium, fentanyl and propofol.

- Patients with normal renal function (creatinine clearance > 60 mL/min).

- Patients with normal liver function.

Exclusion Criteria:

- Patients who were in use of fluoxetine, carbamazepine, aminoglycoside antibiotics,

OATP1A2 inhibitors.

- Patients with gastrointestinal and liver diseases, neuromuscular disorders.

- Patients who were in chronic use of drugs which alter rocuronium effect.

Locations and Contacts

Natalia V. de Moraes, Prof., Phone: +55 16 3301 4689, Email: nmoraes@fcfar.unesp.br

Universidade Estadual Paulista Júlio de Mesquita Filho, Araraquara, São Paulo 14801902, Brazil; Recruiting
Natalia V. de Moraes, Prof., Phone: +55 16 3301 4689, Email: nmoraes@fcfar.unesp.br
Additional Information

Starting date: February 2014
Last updated: March 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017